Consideration of Individualized Treatment of Breast Cancer in Age Less Than 35 Years Women_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 李波 ,  华彬 , 陈悦

卫生部北京医院乳腺中心（北京 100730）;

Corresponding author：

华彬, Email: huabinbjh@126.com

Keywords：

乳腺癌; 个体化治疗; 年轻

DOI：

10.7507/1007-9424.20140131

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李波, 华彬, 陈悦. Consideration of Individualized Treatment of Breast Cancer in Age Less Than 35 Years Women. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(5): 539-543. doi: 10.7507/1007-9424.20140131 Copy

1.	Han W, Kim SW, Park IA, et al.Young age:an independent risk factor for disease-free survival in women with operable breast cancer[J].BMC Cancer, 2004, 4:82.
2.	Han W, Kang SY; Korean Breast Cancer Society.Relationship between age at diagnosis and outcome of premenopausal breast cancer:age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer[J].Breast Cancer Res Treat, 2010, 119(1):193-200.
3.	Kim EK, Noh WC, Han W, et al.Prognostic significance of young age ( < 35 years) by subtype based on ER, PR, and HER2 status in breast cancer:a nationwide registry-based study[J].World J Surg, 2011, 35(6):1244-1253.
4.	Kim IK, Park S, Hwang H, et al.Clinical significance of age at the time of diagnosis among young breast cancer patients[J].J Breast Cancer, 2011, 14(4):314-321.
5.	Althuis MD, Brogan DD, Coates RJ, et al.Breast cancers among very young premenopausal women (United States)[J].Cancer Causes Control, 2003, 14(2):151-160.
6.	Rodriguez AO, Chew H, Cress R, et al.Evidence of poorer survival in pregnancy-associated breast cancer[J].Obstet Gynecol, 2008, 112(1):71-78.
7.	Antoniou A, Pharoah PD, Narod S, et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:a combined analysis of 22 studies[J].Am J Hum Genet, 2003, 72(5):1117-1130.
8.	Lalloo F, Varley J, Moran A, et al.BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives[J].Eur J Cancer, 2006, 42(8):1143-1150.
9.	Imkampe AK, Bates T.Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis[J].Breast J, 2010, 16(2):156-161.
10.	Eng-Wong J, Orzano-Birgani J, Chow CK, et al.Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer[J].Cancer Epidemiol Biomarkers Prev, 2008, 17(7):1696-1701.
11.	Samphao S, Wheeler AJ, Rafferty E, et al.Diagnosis of breast cancer in women age 40 and younger:delays in diagnosis result from underuse of genetic testing and breast imaging[J].Am J Surg, 2009, 198(4):538-543.
12.	华彬, 陆旭, 李波, 等.老年女性乳腺癌患者临床病理特点分析[J].中华老年医学杂志, 2013, 32(5):536-539.
13.	Li J, Xing P, Feng L, et al.The value of substratified combined imaging assessment with mammography and ultrasonography for Chinese women with palpable breast masses[J].Breast Cancer Res Treat, 2014, 12.[Epub ahead of print].
14.	Saslow D, Boetes C, Burke W, et al.American cancer society guidelines for breast screening with MRI as an adjunct to mammography[J].CA Cancer J Clin, 2007, 57(2):75-89.
15.	Adami HO, Malker B, Holmberg L, et al.The relation between survival and age at diagnosis and breast cancer[J].N Engl J Med, 1986, 315(9):559-563.
16.	El Saghir NS, Seoud M, Khalil MK, et al.Effects of young age at presentation on survival in breast cancer[J].BMC Cancer, 2006, 6:194-201.
17.	Lund MJ, Trivers KF, Porter PL, et al.Race and triple negative threats to breast cancer survival:a population-based study in Atlanta, GA[J].Breast Cancer Res Treat, 2009, 113(2):357-370.
18.	Collins LC, Marotti JD, Gelber S, et al.Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer[J].Breast Cancer Res Treat, 2012, 131(3):1061-1066.
19.	Margenthaler J.Younger women diagnosed with early-stage breast cancer more likely to die than older women[C].San Francisco, CA.American College of Surgeons Clinical Congress, October 12-16, 2008.
20.	Chen S, Parmigiani G.Meta-analysis of BRCA1 and BRCA2 penetrance[J].J Clin Oncol, 2007, 25(11):1329-1333.
21.	Evans DG, Moran A, Hartley R, et al.Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status[J].Br J Cancer, 2010, 102(7):1091-1098.
22.	Lakhani SR, Van De Vijver MJ, Jacquemier J, et al.The pathology of familial breast cancer:predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2[J].J Clin Oncol, 2002, 20(9):2310-2318.
23.	Lidereau R, Eisinger F, Champème MH, et al.Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer[J].Cancer Res, 2000, 60(5):1206-1210.
24.	Nijenhuis MV, Rutgers EJ.Who should not undergo breast conservation[J].Breast, 2013, Suppl 2:S110-S114.
25.	Voogd AC, Nielsen M, Peterse JL, et al.Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stageⅠandⅡbreast cancer:pooled results of two large European randomized trials[J].J Clin Oncol, 2001, 19(6):1688-1697.
26.	Xiong Q, Valero V, Kau V, et al.Female patients with breast carcinoma age 30 years and younger have a poor prognosis:the M.D.Anderson Cancer Center experience[J].Cancer, 2001, 92(10):2523-2528.
27.	Early Breast Cancer Trialists' Collaborative Group.Polychemotherapy for early breast cancer:an overview of the randomised trials[J].Lancet, 1998, 352(9132):930-942.
28.	Levine MN, Bramwell VH, Pritchard KI, et al; National Cancer Institute of Canada Clinical Trials Group.Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer[J].J Clin Oncol, 1998, 16(8):2651-2658.
29.	Mamounas EP, Bryant J, Lembersky B, et al.Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B-28[J].J Clin Oncol, 2005, 23(16):3686-3696.
30.	Martin M, Pienkowski T, Mackey J, et al.Adjuvant docetaxel for node-positive breast cancer[J].N Engl J Med, 2005, 352(22):2302-2313.
31.	Davies C, Pan H, Godwin J, et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:Atlas, a randomised trial[J].Lancet, 2013, 381(9869):805-816.
32.	Goldhirsch A.Personalized adjuvant therapies:lessons from the past[J].Breast, 2013, Supp 2:S3-S7.
33.	Jankowitz RC, Mcguire KP, Davidson NE.Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer[J].Breast, 2013, 22(Suppl 2):S165-S170.
34.	Whelan TJ, Pignol JP, Levine MN, et al.Long-term results of hypofractionated radiation therapy for breast cancer[J].N Engl J Med, 2010, 362(6):513-520.
35.	Smith BD, Arthur DW, Buchholz TA, et al.Accelerated partial breast irradiation consensus statement from the American society for radiation oncology (ASTRO)[J].J Am Coll Surg, 2009, 209(2):269-277.
36.	Polgár C, Van Limbergen E, Pötter R, et al.Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery:recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)[J].Radiother Oncol, 2010, 94(3):264-273.
37.	Alshami HA, Kadasne AR, Khalfan M, et al.Pregnancy outcome in late maternal age in a high-income developing country[J].Arch Gynecol Obstet, 2011, 284(5):1113-1116.
38.	Koyama H, Wada T, Nishizawa Y, et al.Cyclophosphamideinduced ovarian failure and its therapeutic significance in patients with breast cancer[J].Cancer, 1977, 39(4):1403-1409.
39.	Sukumvanich P, Case LD, Van Zee K, et al.Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment:a prospective study[J].Cancer, 2010, 116(13):3102-3111.
40.	Azim HA, Peccatori FA, Liptrott SJ, et al.Breast cancer and pregnancy:how safe is trastuzumab?[J].Nat Rev Clin Oncol, 2009, 6(6):367-370.
41.	Pagani O, Partridge A, Korde L, et al.Pregnancy after breast cancer:if you wish, Ma'am[J].Breast Cancer Res Treat, 2011, 129(2):309-317.
42.	Gerber B, von Minckwitz G, Stehle H, et al.Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy:the GBG 37 ZORO study[J].J Clin Oncol, 2011, 29(17):2334-2341.
43.	Dittrich R, Lotz L, Keck G, et al.Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation[J].Fertil Steril, 2012, 97(2):387-390.
44.	Oktay K.Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation[J].J Clin Oncol, 2005, 23(16):3858-3859.
45.	Picton HM, Harris SE, Muruvi W, et al.The in vitro growth and maturation of follicles[J].Reproduction, 2008, 136(6):703-715.
46.	White YA, Woods DC, Takai Y, et al.Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women[J].Nat Med, 2012, 18(3):413-421.
47.	Anders CK, Johnson R, Litton J, et al.Breast cancer before age 40 years[J].Semin Oncol, 2009, 36(3):237-249.
48.	Biffl WL, Myers A, Franciose RJ, et al.Is breast cancer in young Latinas a different disease?[J].Am J Surg, 2001, 182(6):596-600.
49.	Foo CS, Su D, Chong CK, et al.Breast cancer in young Asian women:study on survival[J].Aust N Z J Surg, 2005, 75(7):566-572.
50.	Lee KD, Chen SC, Chan CH, et al.Increased risk for second primary malignancies in women with breast cancer diagnosed at young age:a population-based study in Taiwan[J].Cancer Epidemiol Biomarkers Prev, 2008, 17(10):2647-2655.
51.	Hooning MJ, Aleman BM, Hauptmann M, et al.Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer[J].J Clin Oncol, 2008, 26(34):5561-5568.

1. Han W, Kim SW, Park IA, et al.Young age:an independent risk factor for disease-free survival in women with operable breast cancer[J].BMC Cancer, 2004, 4:82.
2. Han W, Kang SY; Korean Breast Cancer Society.Relationship between age at diagnosis and outcome of premenopausal breast cancer:age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer[J].Breast Cancer Res Treat, 2010, 119(1):193-200.
3. Kim EK, Noh WC, Han W, et al.Prognostic significance of young age ( < 35 years) by subtype based on ER, PR, and HER2 status in breast cancer:a nationwide registry-based study[J].World J Surg, 2011, 35(6):1244-1253.
4. Kim IK, Park S, Hwang H, et al.Clinical significance of age at the time of diagnosis among young breast cancer patients[J].J Breast Cancer, 2011, 14(4):314-321.
5. Althuis MD, Brogan DD, Coates RJ, et al.Breast cancers among very young premenopausal women (United States)[J].Cancer Causes Control, 2003, 14(2):151-160.
6. Rodriguez AO, Chew H, Cress R, et al.Evidence of poorer survival in pregnancy-associated breast cancer[J].Obstet Gynecol, 2008, 112(1):71-78.
7. Antoniou A, Pharoah PD, Narod S, et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:a combined analysis of 22 studies[J].Am J Hum Genet, 2003, 72(5):1117-1130.
8. Lalloo F, Varley J, Moran A, et al.BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives[J].Eur J Cancer, 2006, 42(8):1143-1150.
9. Imkampe AK, Bates T.Impact of a raised body mass index on breast cancer survival in relation to age and disease extent at diagnosis[J].Breast J, 2010, 16(2):156-161.
10. Eng-Wong J, Orzano-Birgani J, Chow CK, et al.Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer[J].Cancer Epidemiol Biomarkers Prev, 2008, 17(7):1696-1701.
11. Samphao S, Wheeler AJ, Rafferty E, et al.Diagnosis of breast cancer in women age 40 and younger:delays in diagnosis result from underuse of genetic testing and breast imaging[J].Am J Surg, 2009, 198(4):538-543.
12. 华彬, 陆旭, 李波, 等.老年女性乳腺癌患者临床病理特点分析[J].中华老年医学杂志, 2013, 32(5):536-539.
13. Li J, Xing P, Feng L, et al.The value of substratified combined imaging assessment with mammography and ultrasonography for Chinese women with palpable breast masses[J].Breast Cancer Res Treat, 2014, 12.[Epub ahead of print].
14. Saslow D, Boetes C, Burke W, et al.American cancer society guidelines for breast screening with MRI as an adjunct to mammography[J].CA Cancer J Clin, 2007, 57(2):75-89.
15. Adami HO, Malker B, Holmberg L, et al.The relation between survival and age at diagnosis and breast cancer[J].N Engl J Med, 1986, 315(9):559-563.
16. El Saghir NS, Seoud M, Khalil MK, et al.Effects of young age at presentation on survival in breast cancer[J].BMC Cancer, 2006, 6:194-201.
17. Lund MJ, Trivers KF, Porter PL, et al.Race and triple negative threats to breast cancer survival:a population-based study in Atlanta, GA[J].Breast Cancer Res Treat, 2009, 113(2):357-370.
18. Collins LC, Marotti JD, Gelber S, et al.Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer[J].Breast Cancer Res Treat, 2012, 131(3):1061-1066.
19. Margenthaler J.Younger women diagnosed with early-stage breast cancer more likely to die than older women[C].San Francisco, CA.American College of Surgeons Clinical Congress, October 12-16, 2008.
20. Chen S, Parmigiani G.Meta-analysis of BRCA1 and BRCA2 penetrance[J].J Clin Oncol, 2007, 25(11):1329-1333.
21. Evans DG, Moran A, Hartley R, et al.Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status[J].Br J Cancer, 2010, 102(7):1091-1098.
22. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al.The pathology of familial breast cancer:predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2[J].J Clin Oncol, 2002, 20(9):2310-2318.
23. Lidereau R, Eisinger F, Champème MH, et al.Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer[J].Cancer Res, 2000, 60(5):1206-1210.
24. Nijenhuis MV, Rutgers EJ.Who should not undergo breast conservation[J].Breast, 2013, Suppl 2:S110-S114.
25. Voogd AC, Nielsen M, Peterse JL, et al.Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stageⅠandⅡbreast cancer:pooled results of two large European randomized trials[J].J Clin Oncol, 2001, 19(6):1688-1697.
26. Xiong Q, Valero V, Kau V, et al.Female patients with breast carcinoma age 30 years and younger have a poor prognosis:the M.D.Anderson Cancer Center experience[J].Cancer, 2001, 92(10):2523-2528.
27. Early Breast Cancer Trialists' Collaborative Group.Polychemotherapy for early breast cancer:an overview of the randomised trials[J].Lancet, 1998, 352(9132):930-942.
28. Levine MN, Bramwell VH, Pritchard KI, et al; National Cancer Institute of Canada Clinical Trials Group.Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer[J].J Clin Oncol, 1998, 16(8):2651-2658.
29. Mamounas EP, Bryant J, Lembersky B, et al.Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B-28[J].J Clin Oncol, 2005, 23(16):3686-3696.
30. Martin M, Pienkowski T, Mackey J, et al.Adjuvant docetaxel for node-positive breast cancer[J].N Engl J Med, 2005, 352(22):2302-2313.
31. Davies C, Pan H, Godwin J, et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:Atlas, a randomised trial[J].Lancet, 2013, 381(9869):805-816.
32. Goldhirsch A.Personalized adjuvant therapies:lessons from the past[J].Breast, 2013, Supp 2:S3-S7.
33. Jankowitz RC, Mcguire KP, Davidson NE.Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer[J].Breast, 2013, 22(Suppl 2):S165-S170.
34. Whelan TJ, Pignol JP, Levine MN, et al.Long-term results of hypofractionated radiation therapy for breast cancer[J].N Engl J Med, 2010, 362(6):513-520.
35. Smith BD, Arthur DW, Buchholz TA, et al.Accelerated partial breast irradiation consensus statement from the American society for radiation oncology (ASTRO)[J].J Am Coll Surg, 2009, 209(2):269-277.
36. Polgár C, Van Limbergen E, Pötter R, et al.Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery:recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)[J].Radiother Oncol, 2010, 94(3):264-273.
37. Alshami HA, Kadasne AR, Khalfan M, et al.Pregnancy outcome in late maternal age in a high-income developing country[J].Arch Gynecol Obstet, 2011, 284(5):1113-1116.
38. Koyama H, Wada T, Nishizawa Y, et al.Cyclophosphamideinduced ovarian failure and its therapeutic significance in patients with breast cancer[J].Cancer, 1977, 39(4):1403-1409.
39. Sukumvanich P, Case LD, Van Zee K, et al.Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment:a prospective study[J].Cancer, 2010, 116(13):3102-3111.
40. Azim HA, Peccatori FA, Liptrott SJ, et al.Breast cancer and pregnancy:how safe is trastuzumab?[J].Nat Rev Clin Oncol, 2009, 6(6):367-370.
41. Pagani O, Partridge A, Korde L, et al.Pregnancy after breast cancer:if you wish, Ma'am[J].Breast Cancer Res Treat, 2011, 129(2):309-317.
42. Gerber B, von Minckwitz G, Stehle H, et al.Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy:the GBG 37 ZORO study[J].J Clin Oncol, 2011, 29(17):2334-2341.
43. Dittrich R, Lotz L, Keck G, et al.Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation[J].Fertil Steril, 2012, 97(2):387-390.
44. Oktay K.Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation[J].J Clin Oncol, 2005, 23(16):3858-3859.
45. Picton HM, Harris SE, Muruvi W, et al.The in vitro growth and maturation of follicles[J].Reproduction, 2008, 136(6):703-715.
46. White YA, Woods DC, Takai Y, et al.Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women[J].Nat Med, 2012, 18(3):413-421.
47. Anders CK, Johnson R, Litton J, et al.Breast cancer before age 40 years[J].Semin Oncol, 2009, 36(3):237-249.
48. Biffl WL, Myers A, Franciose RJ, et al.Is breast cancer in young Latinas a different disease?[J].Am J Surg, 2001, 182(6):596-600.
49. Foo CS, Su D, Chong CK, et al.Breast cancer in young Asian women:study on survival[J].Aust N Z J Surg, 2005, 75(7):566-572.
50. Lee KD, Chen SC, Chan CH, et al.Increased risk for second primary malignancies in women with breast cancer diagnosed at young age:a population-based study in Taiwan[J].Cancer Epidemiol Biomarkers Prev, 2008, 17(10):2647-2655.
51. Hooning MJ, Aleman BM, Hauptmann M, et al.Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer[J].J Clin Oncol, 2008, 26(34):5561-5568.

Previous Article
Application of Molecular Targeted Drugs in Neoadjuvant Treatment of Breast Cancer
Next Article
Diagnosis and Treatment for Occult Breast Cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Consideration of Individualized Treatment of Breast Cancer in Age Less Than 35 Years Women

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content